<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03255330</url>
  </required_header>
  <id_info>
    <org_study_id>GNB-2015</org_study_id>
    <nct_id>NCT03255330</nct_id>
  </id_info>
  <brief_title>The Effect of Gabapentin Used as a Preemptive to the Emergence and Development Chronic Neuropathic Pain in Patients After Spinal Cord Trauma</brief_title>
  <acronym>GabaNeuBol</acronym>
  <official_title>The Effect of Gabapentin Used as a Preemptive to the Emergence and Development Chronic Neuropathic Pain in Patients After Spinal Cord Trauma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masaryk University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masaryk University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of the effect of gabapentin used as a preemptive to the emergence and development
      chronic neuropathic pain in patients after spinal cord trauma
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2017</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment the analgesic effect of gabapentin</measure>
    <time_frame>in 3 months after initiation of the gabapentin treatment</time_frame>
    <description>The decrease of the incidence of chronic neuropathic pain in 3 months after initiation of the gabapentin treatment in 3 months after initiation of the gabapentin treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The decrease of the incidence of chronic neuropathic pain</measure>
    <time_frame>in 6., 9. and 12. months after initiation of the gabapentin treatment</time_frame>
    <description>The decrease of the incidence of chronic neuropathic pain in 6., 9. and 12. months after initiation of the gabapentin treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of painful episodes</measure>
    <time_frame>in 3., 6., 9. and 12. months after initiation of the gabapentin treatment</time_frame>
    <description>The number of painful episodes requiring treatment of rescue medication (in 3., 6., 9. and 12. months after initiation of the gabapentin treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The decrease of the consumption of rescue medication</measure>
    <time_frame>in 3., 6., 9. and 12. months after initiation of the gabapentin treatment</time_frame>
    <description>The decrease of the consumption of rescue medication in 3., 6., 9. and 12. months after initiation of the gabapentin treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and percentage change in average pain</measure>
    <time_frame>in 3., 6., 9. and 12. months</time_frame>
    <description>Absolute and percentage change in average pain after initiation of therapy with gabapentin (baseline) in 3., 6., 9. and 12. months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>in week 1, 3., 6., 9. and 12. months after initiation of the gabapentin treatment</time_frame>
    <description>Quality of life, assessment of neurological pain and psychological state measured by questionnaires PainDETECT, SQUALA and SCL-R</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chronic Pain Due to Trauma</condition>
  <condition>Spinal Cord Injuries</condition>
  <arm_group>
    <arm_group_label>Arm G1800</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administration of gabapentin with a gradual increasing dose of up to 1800 mg / day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G0</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standardized medical treatment of central neuropathic pain: metamizole, tramadol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Gabapentin will be given approximately 3 months until no chronic neuropathic pain is present</description>
    <arm_group_label>Arm G1800</arm_group_label>
    <other_name>Gabapentinum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metamizol</intervention_name>
    <description>Standardized treatment</description>
    <arm_group_label>G0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol</intervention_name>
    <description>Standardized treatment</description>
    <arm_group_label>G0</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women, age 18 - 65 years

          2. Signed written informed consent

          3. Patients after complete/non-complete spinal lesion, after surgery

          4. Patients with spinal cord trauma caused mechanically demanding (due a injury of a bone
             fragment, a disk, a translation spinal canal)

          5. Patient willing and able to comply with the study protocol

          6. Male and females with a highly effective method of birth control plus an additional
             barrier method

        Exclusion Criteria:

          1. Patients with spinal cord lesion ischemic etiology

          2. Pregnant women, nursing or childbearing age with a positive pregnancy test input

          3. Patients unable or unwilling to comply with the study protocol

          4. Acute pancreatitis in 1 year from the start of the study

          5. Chronic pancreatitis in the case history

          6. Active or uncontrolled infectious diseases

          7. Hypersensitivity to any component of the investigational product

          8. Active autoimmune disease

          9. Serious neurological disease with the incidence chronic neuropathic pain
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fakultn√≠ nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2017</study_first_submitted>
  <study_first_submitted_qc>August 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2017</study_first_posted>
  <last_update_submitted>August 18, 2017</last_update_submitted>
  <last_update_submitted_qc>August 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Tramadol</mesh_term>
    <mesh_term>Dipyrone</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

